Clinical Trial

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-04-25; most recent amendment 2025-11-26.
Status change: Not Yet Recruiting → Recruiting 2025-01-30
Trial Details
NCT Number NCT06390956
Lead Sponsor University of Utah
Collaborators: Eli Lilly and Company
Conditions Marginal Zone Lymphoma
Enrollment 23 participants
Start Date 2025-02-20
Primary Completion 2031-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-04